Pillar Biosciences Revenue and Competitors

Claim your profile

Natick, MA USA

Location

$65.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Pillar Biosciences's estimated annual revenue is currently $13.9M per year.(i)
  • Pillar Biosciences received $18.0M in venture funding in May 2016.
  • Pillar Biosciences's estimated revenue per employee is $155,000
  • Pillar Biosciences's total funding is $65.9M.

Employee Data

  • Pillar Biosciences has 90 Employees.(i)
  • Pillar Biosciences grew their employee count by 11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-94%N/AN/A
#2
$2.6M17N/AN/AN/A
#3
$6M39-20%$176.5MN/A
#4
$4.5M29N/AN/AN/A
#5
$2.6M17N/AN/AN/A
#6
N/A145-21%$39.5MN/A
#7
N/A0N/A$9.5MN/A
#8
$15.9M159-39%$135MN/A
#9
$1.7M1157%$20.9MN/A
#10
$2.8M1850%$28.9MN/A

Pillar Biosciences aims to "Make Precision Medicine Accessible" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today's high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.

keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals

$65.9M

Total Funding

90

Number of Employees

$13.9M

Revenue (est)

11%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Pillar Biosciences News

0000-00-00 - Pillar Biosciences seeks to make precision medicine a first-line therapy for cancer patients

Randy Pritchard, Pillar Biosciences CEO, highlighted some of the progress the oncology solutions company has made in developing in-vitro diagnostics, in response to emailed questions from MedCity News. Why did you join Pillar Biosciences? I am incredibly impressed with the technology and the a ...

2016-05-11 - Pillar Biosciences Raises US$18M in Venture Capital

Pillar Biosciences Inc., a Natick, MA-based startup specialized in next generation sequencing (“NGS”)-based clinical oncology testing, received US$18m in venture capital. ORI Capital’s ORI Healthcare Fund made the investment. The company intends to use the funds to continue its R&D efforts in ...

2020-05-12 - Pillar Biosciences Raises $29.7M in Series C Financing

Pillar Biosciences, a Natick, Mass.- and Shanghai, China-based NGS clinical cancer diagnostics company, closed a $29.7m Series C financing. The round was led by ORI Healthcare Fund. The company intends to use the funds to accelerate the expansion of in vitro diagnostic and research use only pa ...

09/03/2019 - Columbia University Medical Center Receives Conditional Approval by the New York State Department of Health for a Custom Pillar Biosciences NGS Panel

BOSTON, May 30, 2019 /PRNewswire/ -- Pillar Biosciences, a clinical cancer diagnostics company based near Boston, MA, announced today ...

01/10/2019 - Pillar Biosciences enters strategic partnership with China ...

SAN FRANCISCO, Jan. 10, 2019 /PRNewswire/ -- Pillar Biosciences, Inc., a clinical cancer diagnostics company based in Boston, MA, USA ...

09/03/2019 - DxPx partners with MyBioGate for China

... Pillar Biosciences, Medicover, and Hightech Gründerfund, Europe's leading startup investor, McDermott Will & Emery as well as Aescuvest.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$19.7M9474%N/A
#2
N/A1073%N/A
#3
$26.7M117-1%N/A
#4
$12.2M122-2%N/A
#5
$24.5M1368%N/A

Pillar Biosciences Funding

DateAmountRoundLead InvestorsReference
2016-05-12$18.0MUndisclosedORI Healthcare Fund L.PArticle